Today Aethlon Medical Inc (NASDAQ:AEMD) Reported Decrease in Shorted Shares

June 17, 2018 - By Michael Collier

Aethlon Medical, Inc. (NASDAQ:AEMD) Logo

The stock of Aethlon Medical Inc (NASDAQ:AEMD) registered a decrease of 1% in short interest. AEMD’s total short interest was 1.59 million shares in June as published by FINRA. Its down 1% from 1.61 million shares, reported previously. With 109,000 shares average volume, it will take short sellers 15 days to cover their AEMD’s short positions.

The stock decreased 0.76% or $0.01 during the last trading session, reaching $1.31. About 80,725 shares traded. Aethlon Medical, Inc. (NASDAQ:AEMD) has declined 33.15% since June 17, 2017 and is downtrending. It has underperformed by 45.72% the S&P500.

Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company has market cap of $23.27 million. The firm is developing Aethlon Hemopurifier, a clinical-stage therapeutic device for the single-use removal of life-threatening viruses from the circulatory system of infected individuals. It currently has negative earnings. It is also involved in the development of exosome products to diagnose and monitor neurological disorders and cancer; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection.

More recent Aethlon Medical, Inc. (NASDAQ:AEMD) news were published by: Benzinga.com which released: “Earnings Scheduled For June 8, 2018” on June 08, 2018. Also Prnewswire.com published the news titled: “Aethlon Medical Announces Fiscal 2018 Results” on June 08, 2018. Seekingalpha.com‘s news article titled: “Aethlon Medical, Inc. (AEMD) CEO Jim Joyce on Q4 2018 Results – Earnings Call Transcript” with publication date: June 08, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: